Vertex builds in gene editing yet again, with $1.2bn Arbor dealVertex Pharma has ramped up its involvement in gene-editing medicines for the third time in a matter of Share XVertex builds in gene editing yet again, with $1.2bn Arbor dealhttps://pharmaphorum.com/news/vertex-builds-in-gene-editing-yet-again-with-1-2bn-arbor-deal/
Intellia, Regeneron ace first trial with ‘in vivo’ CRISPR drugThe first ever clinical data with a CRISPR/Cas9 drug used to edit the genomes of cells within the Share XIntellia, Regeneron ace first trial with ‘in vivo’ CRISPR drughttps://pharmaphorum.com/news/intellia-regeneron-ace-first-trial-with-in-vivo-crispr-drug/
Vertex eyes controllable genetic drugs with $1.3bn Obsidian allianceVertex Pharma has ramped up its involvement in gene-editing medicines for the second time in a week, paying Share XVertex eyes controllable genetic drugs with $1.3bn Obsidian alliancehttps://pharmaphorum.com/news/vertex-eyes-controllable-genetic-drugs-with-1-3bn-obsidian-alliance/
ASH: CRISPR, Vertex’ CTX001 hits the mark in red cell disordersA gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has achieved “remarkable” improvements in patients with beta Share XASH: CRISPR, Vertex’ CTX001 hits the mark in red cell disordershttps://pharmaphorum.com/news/ash-crispr-vertex-ctx001-hits-the-mark-in-red-cell-disorders/
Biogen teams up with gene-editing startup Scribe on ALS programmeScribe Therapeutics, a start-up focusing on gene-editing using CRISPR/Cas9, has burst onto the biotech scene with a $415 Share XBiogen teams up with gene-editing startup Scribe on ALS programmehttps://pharmaphorum.com/news/biogen-teams-up-with-gene-editing-startup-scribe-on-als-programme/
CRISPR pioneers Doudna and Charpentier claim Nobel chemistry prizeDrs Emmanuelle Charpentier and Jennifer Doudna have won this year’s Nobel Prize for chemistry in recognition of their Share XCRISPR pioneers Doudna and Charpentier claim Nobel chemistry prizehttps://pharmaphorum.com/news/crispr-pioneers-doudna-and-charpentier-claim-nobel-chemistry-prize/
First patient dosed in trial of Allergan/Editas’ CRISPR blindness drugA first patient has been treated in a trial of an Allergan and Editas drug based on CRISPR/Cas9, Share XFirst patient dosed in trial of Allergan/Editas’ CRISPR blindness drughttps://pharmaphorum.com/news/first-patient-dosed-in-trial-of-allergan-editas-crispr-blindness-drug/
CRISPR trials yield encouraging data in blood disordersData on the first two patients to be treated with a CRISPR-based drug for the blood disorders beta Share XCRISPR trials yield encouraging data in blood disordershttps://pharmaphorum.com/news/crispr-trials-yield-encouraging-data-in-blood-disorders/
Broad, MilliporeSigma issue call to make access to CRISPR freerGene-editing with CRISPR/Cas9 is promising a revolution in medicine, but battles over intellectual property (IP) have made it Share XBroad, MilliporeSigma issue call to make access to CRISPR freerhttps://pharmaphorum.com/news/broad-milliporesigma-issue-call-to-make-access-to-crispr-freer/
